Saturday 17 October 2026
Export ATYR’s income statement to Excel — free account
aTyr Pharma, Inc.
ATYR Healthcare Biotechnology
aTyr Pharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $190,000.00, down 19.1% from fiscal 2024. In the quarter to June 2026, revenue fell 90.8%, EPS grew 50.0%, free cash flow grew 32.2% and total debt fell 94.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.17
0.01
−5.56%
Follow ATYR
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
Piotroski F-Score |
2 | 1 | — | — | — | — | — | — | — | — |
Altman Z-Score |
(9.34) | (3.20) | (4.57) | (5.23) | — | (9.46) | (13.37) | — | — | — |
P/S ratio |
6.50 | 20.64 | 6.21 | 5.25 | — | 3.40 | 0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
(19.52) | (15.37) | (7.85) | (9.83) | — | (21.67) | (28.40) | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
P/Operating CF |
(5.95) | (20.47) | (7.27) | (6.47) | — | (6.58) | (2.85) | — | — | — |
Beneish M-Score |
(3.76) | (2.59) | (3.91) | — | — | 18.67 | — | — | — | — |
P/B ratio |
1.08 | 3.85 | 0.89 | 0.94 | — | 1.13 | 0.67 | — | — | — |
Price to Tangible BV |
1.08 | 3.85 | 0.89 | 0.94 | — | 1.13 | 0.67 | — | — | — |
EV/Sales |
(0.25) | 15.40 | (1.03) | 0.39 | — | 0.79 | 0.00 | — | — | — |
EV/EBITDA |
0.04 | 0.00 | 0.24 | 0.00 | — | 0.00 | 0.26 | — | — | — |
EV/Operating CF |
0.05 | (2.90) | 0.40 | (0.12) | — | (0.54) | 0.27 | — | — | — |
EV/FCF |
0.05 | (2.90) | 0.35 | (0.12) | — | (0.54) | 0.27 | — | — | — |
Quick Ratio |
5.25 | 4.93 | 6.13 | 5.62 | 18.02 | 5.75 | 2.42 | 4.57 | 8.19 | 8.46 |
Current Ratio |
5.30 | 5.48 | 6.27 | 5.83 | 18.89 | 6.06 | 2.47 | 4.69 | 8.37 | 8.77 |
Net Debt/EBITDA |
1.01 | 1.03 | 1.75 | 1.47 | 3.32 | 2.14 | 1.36 | 1.07 | 1.43 | 1.11 |
Debt/Assets |
0.28% | 0.92% | 1.18% | 1.05% | 0.34% | 3.56% | 6.19% | 30.39% | 22.08% | 11.84% |
Debt/Equity |
0.00 | 0.01 | 0.02 | 0.01 | 0.00 | 0.04 | 0.11 | 0.48 | 0.31 | 0.15 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.10 | 0.00 | 0.28 | 0.01 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.84 | 1.08 | 0.66 | 0.92 | 0.98 | 0.94 | 0.85 | 0.90 | 0.88 | 0.91 |
Capex/Depreciation |
0.22 | 0.05 | 9.77 | (0.66) | (0.08) | (0.11) | (0.02) | (0.41) | (1.00) | (0.37) |
| (108.11%) | (79.88%) | (62.30%) | (50.26%) | (48.03%) | (61.80%) | (86.34%) | (70.52%) | (75.89%) | (65.06%) | |
| (78.09%) | (58.88%) | (46.56%) | (42.91%) | (43.78%) | (43.31%) | (53.08%) | (48.58%) | (56.75%) | (55.05%) | |
ROIC |
0.00% | 0.00% | 0.00% | (471.97%) | (1,318.00%) | (847.77%) | 0.00% | (15,194.44%) | 0.00% | (18,959.42%) |
Return on Tangible Assets |
(106.87%) | (89.12%) | (54.71%) | (64.71%) | (31.24%) | (53.08%) | (116.43%) | (82.53%) | (61.12%) | (85.50%) |
Average Days of Receivables |
1,677.08 | 2,696.34 | 2,518.81 | 413.81 | 0.00 | 71.18 | 86.49 | — | — | — |
Research and Development Expense of Revenue |
31,694.21% | 23,137.02% | 11,981.02% | 412.17% | 0.00% | 165.38% | 3,328.91% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
9,262.11% | 5,862.55% | 3,676.77% | 134.62% | 0.00% | 86.80% | 2,216.11% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
2,630.00% | 1,271.91% | 736.54% | 20.74% | 0.00% | 14.01% | 422.51% | 0.00% | 0.00% | 0.00% |
Graham Net Nets |
0.75 | 0.20 | 0.91 | 0.84 | — | 0.80 | 1.20 | — | — | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
Earnings Yield |
(101.28%) | (24.03%) | (64.00%) | (67.80%) | — | (40.98%) | (175.80%) | — | — | — |
Free Cash Flow Yield |
(85.58%) | (25.73%) | (46.54%) | (64.63%) | — | (43.57%) | (143.22%) | — | — | — |
Revenue per Share |
0.00 | 0.00 | 0.01 | 0.37 | 0.00 | 1.14 | 0.13 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.67) | (0.93) | (0.62) | (1.47) | (1.73) | (1.67) | (5.96) | (14.50) | (22.96) | (31.26) |
Capex per Share |
0.00 | 0.00 | (0.08) | (0.05) | (0.01) | (0.02) | (0.01) | (0.28) | (0.71) | (0.35) |
Free Cash Flow per Share |
(0.67) | (0.93) | (0.70) | (1.53) | (1.74) | (1.69) | (5.97) | (14.78) | (23.67) | (31.62) |
Cash per Share |
0.85 | 0.97 | 1.83 | 2.33 | 5.66 | 3.46 | 9.28 | 23.13 | 46.14 | 42.67 |
Shareholders Equity per Share |
0.72 | 0.94 | 1.69 | 2.51 | 5.72 | 3.44 | 6.27 | 15.71 | 34.82 | 37.14 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.72 | 0.94 | 1.69 | 2.51 | 5.72 | 3.44 | 6.27 | 15.71 | 34.82 | 37.14 |
Free Cash Flow |
(62.05) | (69.18) | (37.42) | (43.35) | (33.22) | (15.48) | (20.04) | (31.66) | (43.68) | (53.46) |
Working Capital |
65.09 | 66.99 | 86.58 | 67.01 | 107.56 | 29.67 | 19.00 | 39.97 | 76.59 | 66.24 |
Capital Expenditures |
(0.06) | (0.06) | (4.20) | (1.46) | (0.14) | (0.18) | (0.03) | (0.59) | (1.31) | (0.60) |
Net Current Asset Value |
54.52 | 54.96 | 72.81 | 56.37 | 107.16 | 28.29 | 16.76 | 31.71 | 61.88 | 57.05 |
EV/EBIT |
0.04 | 0.00 | 0.24 | 0.00 | — | 0.00 | 0.24 | — | — | — |
Capex to Sales |
0.34 | 0.25 | 11.90 | 0.14 | 0.00 | 0.02 | 0.07 | 0.00 | 0.00 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
(0.07) | (0.24) | (0.08) | 0.73 | 3.08 | 1.92 | 1.41 | 0.78 | 0.58 | 1.13 |
Cash ROIC |
(42.43%) | (48.43%) | (19.69%) | (31.31%) | (15.28%) | (23.99%) | (36.83%) | (31.90%) | (25.83%) | (37.00%) |
Accounts Receivable Turnover |
0.15 | 0.11 | 0.05 | 1.70 | 0.00 | 9.78 | 0.00 | — | — | — |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | — | — | 0.00 | 0.00 | 0.00 |
Average Receivables |
1.30 | 2.09 | 7.11 | 6.11 | 1.24 | 1.07 | 348.66 | — | — | — |
Average Payables |
4.11 | 3.93 | 3.32 | 2.07 | 1.23 | 1.14 | 0.94 | 1.66 | 2.44 | 3.24 |
Average Assets |
94.92 | 108.74 | 108.22 | 105.66 | 77.13 | 37.46 | 44.47 | 71.05 | 84.94 | 105.10 |
Average Common Equity |
68.56 | 80.15 | 80.88 | 90.21 | 70.31 | 26.25 | 27.34 | 48.95 | 63.52 | 88.93 |
Columns are period end dates